Elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least 1 F508del allele: Interim results from a Phase 3 open-label extension study

Category Primary study
JournalJournal of Cystic Fibrosis
Year 2021
This article has no abstract
Epistemonikos ID: 7032116328e5eb51d36b1cac5c4838c668e9f138
First added on: Feb 13, 2025